Evidence map›Paper›PMID 39766181›Full record

ArticleCancers2024

Clinical Introduction of Stem Cell Sparing Radiotherapy to Reduce the Risk of Xerostomia in Patients with Head and Neck Cancer.

Maria I van Rijn-Dekker, Arjen van der Schaaf, Sanne W Nienhuis, Antoinette S Arents-Huls, Rachel B Ger, Olga Hamming-Vrieze, Frank J P Hoebers, Mischa de Ridder, Sabrina Vigorito, Ellen M Zwijnenburg and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maria I van Rijn-DekkerDepartment of Radiation Oncology, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.ORCID 0000-0002-2803-8997
Arjen van der SchaafDepartment of Radiation Oncology, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.ORCID 0000-0003-4067-7975
Sanne W NienhuisDepartment of Radiation Oncology, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
Antoinette S Arents-HulsDepartment of Radiation Oncology, Radiotherapiegroep, 6815 AD Arnhem, The Netherlands.
Rachel B GerRadiation Oncology and Molecular Radiation Sciences, John Hopkins Medicine, Baltimore, MD 21287, USA.
Olga Hamming-VriezeDepartment of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.
Frank J P HoebersDepartment of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University, 6229 ET Maastricht, The Netherlands.
Mischa de RidderDepartment of Radiation Oncology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0000-0002-2530-3038
Sabrina VigoritoUnit of Medical Physics, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Ellen M ZwijnenburgDepartment of Radiation Oncology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-1727-8215
Johannes A LangendijkDepartment of Radiation Oncology, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.ORCID 0000-0003-1083-372X
Peter van LuijkDepartment of Radiation Oncology, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.ORCID 0000-0001-7959-1234
Roel J H M SteenbakkersDepartment of Radiation Oncology, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesStudies have shown that dose to the parotid gland stem cell rich (SCR) regions should be reduced to lower the risk of xerostomia after radiotherapy (RT). This study aimed to assess whether stem cell sparing (SCS)-RT can be adopted in routine clinical practice.

methodsMultiple planning studies were performed to compare SCS-RT with standard (ST)-RT using 30 head and neck cancer patients. Shifts in mean dose to the SCR regions (D

resultsUsing photons, D

conclusionsStem cell sparing radiotherapy can be clinically introduced by making small adjustments to the optimization strategy and can reduce the risk of xerostomia.

Indexed as

head and neck cancerparotid gland stem cellsstem cell sparing radiotherapyxerostomia

Identifiers

PMID39766181
PMCPMC11674908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.